Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies
Maurizio Callari(Cancer Research UK), Giampaolo Bianchini(Vita-Salute San Raffaele University), Alberta Locatelli(Vita-Salute San Raffaele University), Marina Ferrarini(San Raffaele University of Rome), Lajos Pusztai(Yale University), Stefania Zambelli(San Raffaele University of Rome), Balázs Győrffy(Semmelweis University), Barbara Galbardi(Vita-Salute San Raffaele University), Giancarlo Bisagni, Marco Colleoni(European Institute of Oncology), Luca Gianni(Fondazione Michelangelo), Marco Barreca(Fondazione Michelangelo), Pinuccia Valagussa(Fondazione Michelangelo), Matteo Dugo(Fondazione IRCCS Istituto Nazionale dei Tumori), Antonio Frassoldati(Italian Oncology Group of Clinical Research), Lucia Del Mastro(Ospedale Policlinico San Martino), Lucia Viganò(Vita-Salute San Raffaele University), Mauro Mansutti(Hospital Clínico Universitario de Valencia), G. Viale(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Olivia Biasi(Istituti di Ricovero e Cura a Carattere Scientifico), Chiara Dall’Ara(Vita-Salute San Raffaele University), Claudio Zamagni(Policlinico S.Orsola-Malpighi)
Cited by 5
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer
|PLoS ONE|2013|1.9k